PART I Overview We are a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. Our proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer growth, metastasis and progression, and contribute to immunotherapy, chemotherapy and radiotherapy resistance. The DNase technology is designed to targe...
expected 2026-12-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001683168-26-001737 | EDGAR | 67K words |
| 2025-03-18 | 2024-12-31 | 0001683168-25-001686 | EDGAR | 65K words |
| 2024-03-21 | 2023-12-31 | 0001683168-24-001594 | EDGAR | 71K words |
| 2023-03-22 | 2022-12-31 | 0001683168-23-001674 | EDGAR | 75K words |
| 2022-03-22 | 2021-12-31 | 0001683168-22-001839 | EDGAR | 71K words |
| 2021-03-16 | 2020-12-31 | 0001683168-21-000969 | EDGAR | 75K words |
| 2020-03-26 | 2019-12-31 | 0001683168-20-000967 | EDGAR | 75K words |
| 2019-03-29 | 2018-12-31 | 0001683168-19-000840 | EDGAR | 70K words |
| 2018-03-30 | 2017-12-31 | 0001683168-18-000831 | EDGAR | 74K words |
| 2017-03-31 | 2016-12-31 | 0001683168-17-000749 | EDGAR | 76K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001683168-26-006061 | EDGAR | 14K words |
| 2025-11-12 | 2025-09-30 | 0001683168-25-008259 | EDGAR | 14K words |
| 2025-08-12 | 2025-06-30 | 0001683168-25-005983 | EDGAR | 13K words |
| 2025-05-13 | 2025-03-31 | 0001683168-25-003496 | EDGAR | 10K words |
| 2024-11-12 | 2024-09-30 | 0001683168-24-007903 | EDGAR | 13K words |
| 2024-08-13 | 2024-06-30 | 0001683168-24-005572 | EDGAR | 13K words |
| 2024-05-09 | 2024-03-31 | 0001683168-24-003172 | EDGAR | 11K words |
| 2023-11-09 | 2023-09-30 | 0001683168-23-007820 | EDGAR | 15K words |
| 2023-08-10 | 2023-06-30 | 0001683168-23-005513 | EDGAR | 16K words |
| 2023-05-11 | 2023-03-31 | 0001683168-23-003201 | EDGAR | 13K words |
| 2022-11-09 | 2022-09-30 | 0001683168-22-007447 | EDGAR | 18K words |
| 2022-08-11 | 2022-06-30 | 0001683168-22-005567 | EDGAR | 17K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-23 | 0001683168-26-007340 | EDGAR | 5K words |
| 2026-09-16 | 0001683168-26-007181 | EDGAR | 5K words |
| 2026-08-07 | 0001683168-26-006077 | EDGAR | 1K words |
| 2026-03-13 | 0001683168-26-001744 | EDGAR | 1K words |
| 2026-01-09 | 0001683168-26-000196 | EDGAR | 1K words |
| 2025-12-11 | 0001683168-25-009076 | EDGAR | 1K words |
| 2025-11-13 | 0001683168-25-008288 | EDGAR | 1K words |
| 2025-10-14 | 0001683168-25-007528 | EDGAR | 1K words |
| 2025-08-13 | 0001683168-25-006001 | EDGAR | 1K words |
| 2025-05-14 | 0001683168-25-003513 | EDGAR | 1K words |
254 total filings indexed. 222 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001534525 |
| Ticker | XBIO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.xeneticbio.com |
| Listed | 2012-05-16 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/XBIO (~200 tokens, structured JSON with cryptographic provenance)